Drug Trial Radar · NCT05332340
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Nov 16, 2022
Primary completion
Nov 30, 2022
Study completion Nov 30, 2022
Sponsor
- Lead sponsor
- Biozeus Biopharmaceutical S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Azidus Brasil Scientific Research and Development Ltda
- First posted
- Apr 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.
Conditions
- Erectile Dysfunction Following Radical Prostatectomy
- Erectile Dysfunction
- Prostate Cancer
- Radical Prostatectomy
Interventions
BZ371ADrug
Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
- T1/2Time frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
- AUCTime frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
- Clearance (CL)Time frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
- VdTime frame: 0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
- Adverse Effects EvaluationTime frame: All adverse effect will be collected from the beginning of the study up to one week after drug administration
- Physical ExamTime frame: Baseline and 1 week
- Change in SBPTime frame: Baseline and 1 week
- Change in DBPTime frame: Baseline and 1 week
- Change in Heart RateTime frame: Baseline and 1 week
- Change in Respiratory RateTime frame: Baseline and 1 week
- Change in TemperatureTime frame: Baseline and 1 week
- Basal Chest Electrocardiogram (ECG)Time frame: Baseline and 1 week
- Blood EvaluationTime frame: Baseline and 1 day
- Urine EvaluationTime frame: Baseline and 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Azidus Brasil Pesquisa Científica e Desenvolvimento
Valinhos, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.